Home/Pipeline/Phenotech Clinical AST Platform

Phenotech Clinical AST Platform

Bacterial Infection Antibiotic Susceptibility Testing

Clinical StudyActive

Key Facts

Indication
Bacterial Infection Antibiotic Susceptibility Testing
Phase
Clinical Study
Status
Active
Company

About Resistell

Resistell is an EPFL spin-off and private diagnostics company based in Basel, Switzerland, focused on addressing the global crisis of antimicrobial resistance. Its core innovation is a nanomotion-based platform that detects bacterial metabolic activity to determine antibiotic susceptibility within one hour, a significant improvement over standard culture-based methods that take 24-48 hours. The company has validated its technology through peer-reviewed publication in Nature Communications, initiated international clinical studies, and formed strategic partnerships with hospitals and foundations. Resistell is positioned in the high-growth AST market, aiming to reduce inappropriate antibiotic use, lower healthcare costs, and save lives.

View full company profile

Therapeutic Areas